The unmet needs of cancer survivors
Dr Jennifer Klemp - University of Kansas Medical Center, Kansas City, USA
The unmet needs of cancer survivors ( Dr Jennifer Klemp - University of Kansas Medical Center, Kansas City, USA )
26 Jul 2017
Precision medicine: a nurses perspective
Adrienne Vazquez - Memorial Sloan Kettering, New York, USA
Precision medicine: a nurses perspective ( Adrienne Vazquez - Memorial Sloan Kettering, New York, USA )
26 Jul 2017
New drug advancements presented at ASCO
Dr Christian Rolfo – Antwerp University, Belgium
New drug advancements presented at ASCO ( Dr Christian Rolfo – Antwerp University, Belgium )
21 Jul 2017
iManageCancer: Psycho-emotional and family resilience monitoring
Dr Chiara Renzi - European Institute of Oncology, Milan, Italy
iManageCancer: Psycho-emotional and family resilience monitoring ( Dr Chiara Renzi - European Institute of Oncology, Milan, Italy )
21 Jul 2017
Celebrating a 10 year partnership: ecancer and the IEO
Prof Gordon McVie - Editor in Chief, ecancer
Celebrating a 10 year partnership: ecancer and the IEO ( Prof Gordon McVie - Editor in Chief, ecancer )
19 Jul 2017
Improving care for cancer patients
Dr David Hui - MD Anderson Cancer Center, Houston, USA
Improving care for cancer patients ( Dr David Hui - MD Anderson Cancer Center, Houston, USA )
14 Jun 2017
Managing cancer and living meaningfully
Dr Gary M. Rodin - UHN Princess Margaret Hospital, Toronto, Canada
Managing cancer and living meaningfully ( Dr Gary M. Rodin - UHN Princess Margaret Hospital, Toronto, Canada )
14 Jun 2017
Stereotactic radiotherapy in primary hepatic cancer
Dr Parag Parikh - Washington University, St. Louis, USA
Stereotactic radiotherapy in primary hepatic cancer ( Dr Parag Parikh - Washington University, St. Louis, USA )
13 Jun 2017
Tivantinib as second line therapy for high-MET HCC
Prof Lorenza Rimassa - Humanitas Cancer Center, Milan, Italy
Tivantinib as second line therapy for high-MET HCC ( Prof Lorenza Rimassa - Humanitas Cancer Center, Milan, Italy )
4 Jun 2017
Results of SUMMIT: a global phII trial of neratinib in HER2/3 mutant solid tumou...
Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA
Results of SUMMIT: a global phII trial of neratinib in HER2/3 mutant solid tumours ( Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA )
10 Apr 2017
Neratinib in HER2 or HER3 mutant solid tumours
Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA
Neratinib in HER2 or HER3 mutant solid tumours ( Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA )
10 Apr 2017
Existing and prospective immunotherapeutics for biliary tract cancer
Prof Junji Furuse - Kyorin University Hospital Cancer Centre, Tokyo, Japan
Existing and prospective immunotherapeutics for biliary tract cancer ( Prof Junji Furuse -  Kyorin University Hospital Cancer Centre, Tokyo, Japan )
3 Jan 2017